ARKG241227C34000
- 0.00
- 0.000.00%
ARK Genomic Revolution ETF Newsroom
Mizuho CEO Sees Global Boom in M&A After Trump Takes Office
2024's 'Biggest Loses' That Could See Reversal in 2025
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Adaptive Biotechnologies Analyst Ratings
New Strategy? Cathie Wood's ARK Purchases Shares in Futu, Significantly Increased Its Stake in AI Healthcare Company Tempus AI and Sold Off Shopify
Cathie Wood's ARK ETF announced the daily Trade details for Tuesday, December 17, 2024.
Natera Analyst Ratings
Annual review | The top ten explosive stocks in the US stock market for 2024 have been released! Applovin emerges as the dark horse of the year in AI, MSTR astonishes the market with a fivefold increase for the year, and Tesla makes a comeback in the last
As of the market close on December 11, the S&P 500 Index has risen by 27% year-to-date, surpassing 6,000 points; the Nasdaq Composite Index has accumulated a rise of over 33%, reaching a milestone of 0.02 million points, exceeding market expectations.
Natera Announces Enrollment Of First Patients In SAGITTARIUS A Randomized Phase III Clinical Trial In Colon Cancer; ~700-900 Patients Expected To Be Enrolled Across More Than 20 Sites
Cathie Wood's Ark Invest Trims Tesla Exposure Amid Searing Rally, Sells $21.8M Worth Of Stock — Bets On This AI Medical Company
Editas Cut to Equal Weight by Wells Fargo Over Reni-cel Positioning
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
Recursion Pharmaceuticals Analyst Ratings
Top 3 Health Care Stocks That May Collapse This Quarter
10 Health Care Stocks With Whale Alerts In Today's Session
What's Going On With Recursion Pharmaceuticals Stock?
Chardan Capital Maintains Buy on CRISPR Therapeutics, Maintains $94 Price Target
CRISPR Therapeutics Analyst Ratings
Beam Therapeutics Analyst Ratings
Vertex Reports Positive Long-term Data for Casgevy
CRISPR Therapeutics Highlights CTX112 Data At ASH 2024, Showcasing Potential Clinical Benefits In R/R CD19-Positive B-Cell Malignancies; Receives FDA RMAT Designation For Follicular And Marginal Zone Lymphomas, With Phase 1 Trial Expanding Into...